Technical Analysis for NBY - NovaBay Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.5689 0.35% 0.00
NBY closed up 7.96 percent on Wednesday, February 19, 2020, on 1.38 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up
Historical NBY trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.35%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.35%
New Uptrend Bullish 0.35%
Pocket Pivot Bullish Swing Setup 0.35%
Wide Bands Range Expansion 0.35%
Up 3 Days in a Row Strength 0.35%
Oversold Stochastic Weakness 0.35%
Bullish Engulfing Bullish 8.34%
Wide Bands Range Expansion 8.34%
Oversold Stochastic Weakness 8.34%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company's Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Medicine Biotechnology Health California Pharmaceutical Products Catheter Acne Urinary Tract Infections Impetigo

Is NBY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.04
52 Week Low 0.1
Average Volume 234,624
200-Day Moving Average 0.79
50-Day Moving Average 0.60
20-Day Moving Average 0.58
10-Day Moving Average 0.54
Average True Range 0.04
ADX 25.67
+DI 23.21
-DI 19.69
Chandelier Exit (Long, 3 ATRs ) 0.59
Chandelier Exit (Short, 3 ATRs ) 0.62
Upper Bollinger Band 0.67
Lower Bollinger Band 0.49
Percent B (%b) 0.43
BandWidth 31.93
MACD Line -0.02
MACD Signal Line -0.02
MACD Histogram -0.0043
Fundamentals Value
Market Cap 8.68 Million
Num Shares 15.3 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 4.39
Price-to-Book 20.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.67
Resistance 3 (R3) 0.67 0.63 0.65
Resistance 2 (R2) 0.63 0.60 0.63 0.65
Resistance 1 (R1) 0.60 0.59 0.61 0.60 0.64
Pivot Point 0.56 0.56 0.57 0.56 0.56
Support 1 (S1) 0.53 0.53 0.54 0.53 0.49
Support 2 (S2) 0.49 0.52 0.49 0.49
Support 3 (S3) 0.46 0.49 0.48
Support 4 (S4) 0.46